left colorectal cancer
Conditions
Interventions
Experimental group:cetuximab plus FOLFIRI/FOLFOX combined with thalidomide
Sponsors
The Third Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing; 2. Physical state is good: PS 0-2; 3. Expected survival of more than 3 months; 4. Aged 18-75 years; 5. Have not received systematic chemotherapy before; 6. Did not receive cetuximab treatment; 7. Liver, kidney and bone marrow functions are basically normal; 8. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks; 9. Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with severe dysfunction of vital organs (heart); 2. Patients with other malignant tumors; 3. Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test); 4. In the active phase of acute or chronic infectious diseases; 5. Patients with a clear history of drug allergy or allergic constitution; 6. Patients participating in other clinical trials; 7. Other conditions in which the patient was considered inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reaction;Early tumor regression, ETS;Disease control rate, DCR;Progressive free survival, PFS;Overall survival, OS;Duration of response, DOR; | — |
Countries
China
Contacts
Public ContactKong Rui
the Third Affiliated Hospital of Chongqing Medical University
Outcome results
None listed